Burning Rock Biotech (BNR) Current Leases (2019 - 2026)

Burning Rock Biotech (BNR) has reported Current Leases for 8 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 1.39% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 1.39% YoY), while the FY2025 annual figure was $2.4 million, down 28.79% from the prior year.
• Current Leases came in at $3.1 million for Q1 2026 at Burning Rock Biotech, up from $2.4 million in the prior quarter.
• The five-year high for Current Leases was $5.7 million in Q2 2022, with the low at $1.2 million in Q4 2023.
• Average Current Leases over 5 years is $3.5 million, with a median of $3.2 million recorded in 2023.
• Across the five-year window, Current Leases plunged 77.1% in 2023 and soared 185.21% in 2024, its largest moves.
• Year by year, Current Leases stood at $5.2 million in 2022, then slumped by 77.1% to $1.2 million in 2023, then jumped by 185.21% to $3.4 million in 2024, then tumbled by 30.9% to $2.4 million in 2025, then gained by 29.52% to $3.1 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $3.1 million, $2.4 million, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.